Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA BIOTECH SERVICES HOLDINGS LIMITED
中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

SUPPLEMENTAL ANNOUNCEMENT TO THE UPDATE ON EXEMPTED CONNECTED TRANSACTION IN RELATION TO THE ADOPTION OF SHARE AWARD SCHEME BY AND SUBSCRIPTION OF SHARES IN A SUBSIDIARY

Reference is made to the announcements (the "**Announcements**") of China Biotech Services Holdings Limited (the "**Company**") dated 5 August 2024 and 31 October 2025 in relation to, among others, the exempted connected transaction in relation to the adoption of the Share Award Scheme by Pengbo (Hainan) and the Subscription Agreement in relation to the subscription of 9% of the issued share capital of Dynamic Healthcare by Jiabao Zhongzhi (Hainan) and the extension of the Long Stop Date of the Subscription Agreement, and the announcement dated 15 May 2026 in relation to the Tripartite Agreement and the 2026 Subscription. Unless otherwise defined, capitalised terms used herein shall have the same meaning as defined in the Announcements.

On 16 June 2026, Dynamic Healthcare, Jiabao Zhongzhi (Hainan) and Pengbo (Hainan) entered into a supplemental agreement (the "**Supplemental Agreement**") to the Tripartite Agreement to amend the subscription amount of the registered capital of Pengbo (Hainan) by Jiabao Zhongzhi (Hainan) from RMB9,300,000 to RMB9,450,000, representing approximately 5.93% of the registered capital of Pengbo (Hainan) at completion of the 2026 Subscription. Save for the proposed amendment, all other terms and conditions under the Tripartite Agreement remain unchanged.

SUPPLEMENTAL AGREEMENT

The principal terms of the Supplemental Agreement are set out below:

Date: 16 June 2026

Parties: (1) Dynamic Healthcare;

(2) Jiabao Zhongzhi (Hainan); and

(3) Pengbo (Hainan)

Subscription amount: The subscription amount of the registered capital of Pengbo (Hainan) by Jiabao Zhongzhi (Hainan) shall be amended from RMB9,300,000 to RMB9,450,000

Shareholding structure upon Completion of the 2026 Subscription (as amended)



REASONS FOR AND BENEFITS OF THE SUPPLEMENTAL AGREEMENT

The amendment of the subscription amount of the registered capital of Pengbo (Hainan) by Jiabao Zhongzhi (Hainan) from RMB9,300,000 to RMB9,450,000 as set out in the Supplemental Agreement is to accommodate to the addition of staff members of Pengbo (Hainan) to the Share Award Scheme.

As such, the Company considers that the Supplemental Agreement and the transactions contemplated thereunder are entered into on normal commercial terms after arm's length negotiations, and the terms and conditions thereof are fair and reasonable and in the interests of the Company and its Shareholders as a whole.

FINANCIAL EFFECTS OF THE 2026 SUBSCRIPTION

As the transactions contemplated under the Tripartite Agreement (as amended by the Supplemental Agreement) will not result in the Company's loss of control over Pengbo (Hainan), and the financial results of Pengbo (Hainan) will continue to be consolidated into the financial results upon completion of the 2026 Subscription and the Tripartite Agreement (as amended by the Supplemental Agreement) will be accounted for as an equity transaction and will not result in the recognition of any gain or loss in the Company's consolidated statement of profit or loss and other comprehensive income. There will be no material financial impact on the Company resulting from the transactions contemplated under the Tripartite Agreement (as amended by the Supplemental Agreement).

GEM LISTING RULES IMPLICATIONS

The 2026 Subscription (as amended by the Supplemental Agreement) constitutes a transaction of the Company under Rule 19.32A(1) of the GEM Listing Rules but as all of the applicable percentage ratios under Rule 19.07 of the GEM Listing Rules do not exceed 5%, the Tripartite Agreement (as amended by the Supplemental Agreement) and the transactions contemplated thereunder does not constitute a notifiable transaction on the part of the Company.

As at the date of this announcement, Mr. Li is a director of CBSH Flourish, and therefore is a connected person of the Company at the subsidiary level under Chapter 20 of the GEM Listing Rules.

Given that Mr. Li is a connected person of the Company at the subsidiary level, the 2026 Subscription (as amended by the Supplemental Agreement) constitutes a connected transaction on the part of the Company under Chapter 20 of the GEM Listing Rules. By virtue of Rule 20.99 of the GEM Listing Rules, as (i) all the applicable percentage ratios under Rule 19.07 of the GEM Listing Rules do not exceed 5%; (ii) Mr. Li is a connected person of the Company at the subsidiary level; (iii) the transactions contemplated under the Tripartite Agreement (as amended by the Supplemental Agreement) are on normal commercial terms; and (iv) the Board (including all the independent non-executive Directors) have approved the transactions and confirmed that the transactions are on normal commercial terms, fair and reasonable and in the interests of the Company and the Shareholders as a whole, the transactions contemplated under the Tripartite Agreement (as amended by the Supplemental Agreement) are subject to reporting and announcement but are exempted from the circular, independent financial advice and independent Shareholders' approval requirements under Chapter 20 of the GEM Listing Rules.

None of the Directors has any interest in the Tripartite Agreement (as amended by the Supplemental Agreement) and none of them are required to abstain from voting on the relevant resolutions of the Board.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 16 June 2026

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Liu Xiaolin (Chairman), Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.